Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$15.09
-1.3%
$0.00
$11.06
$63.00
$298.92M1.5251,993 shs114,029 shs
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
$0.61
$0.39
$2.99
$40.80M1.09137,347 shs88,300 shs
Immunome, Inc. stock logo
IMNM
Immunome
$8.55
-1.6%
$8.66
$5.15
$16.81
$756.14M1.92893,051 shs813,515 shs
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$8.50
$8.47
$3.10
$8.50
$26.35M1.0363,470 shsN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
$1.41
-6.6%
$1.89
$0.87
$10.80
$6.77M0.478,298 shs1,502 shs
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-1.31%-6.56%-98.03%-98.03%-98.03%
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00%0.00%0.00%0.00%0.00%
Immunome, Inc. stock logo
IMNM
Immunome
-1.61%+0.94%-6.35%+37.68%-29.92%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00%0.00%0.00%0.00%0.00%
Orgenesis Inc. stock logo
ORGS
Orgenesis
-6.56%-7.78%-23.73%-28.01%+141,099,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.2611 of 5 stars
3.80.00.03.72.41.70.6
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
2.596 of 5 stars
3.52.00.00.03.22.50.0
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
3.67
Strong Buy$25.0065.67% Upside
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
0.00
N/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
3.00
Buy$23.33172.90% Upside
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.00
N/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest ENOB, ORGS, LMNL, CBIO, and IMNM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/20/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/18/2025
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$22.00
5/13/2025
Immunome, Inc. stock logo
IMNM
Immunome
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$33.00 ➝ $21.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
$10K29,500.95N/AN/A$8.24 per share1.83
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/A$1.37 per shareN/A
Immunome, Inc. stock logo
IMNM
Immunome
$9.04M82.29N/AN/A$2.27 per share3.77
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$310K85.00N/AN/A$8.97 per share0.95
Orgenesis Inc. stock logo
ORGS
Orgenesis
$662K10.23N/AN/A($6.58) per share-0.21
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
-$37.88M-$46.000.00N/AN/AN/A-293.92%-206.20%N/A
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
-$113.43MN/A0.00N/AN/AN/A-154.69%-130.66%N/A
Immunome, Inc. stock logo
IMNM
Immunome
-$292.96M-$3.18N/AN/AN/A-1,875.21%-71.65%-60.36%8/11/2025 (Estimated)
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
$380K$0.2929.31N/A248.35%-88.44%-64.15%N/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
-$55.36MN/A0.00N/A-3,827.81%N/A-130.18%8/6/2025 (Estimated)

Latest ENOB, ORGS, LMNL, CBIO, and IMNM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Immunome, Inc. stock logo
IMNM
Immunome
-$0.66-$0.52+$0.14-$0.52$0.46 million$2.93 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/AN/AN/AN/AN/A
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
N/AN/AN/AN/AN/A
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
N/A
2.29
2.29
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
N/A
0.33
0.33
Immunome, Inc. stock logo
IMNM
Immunome
N/A
10.49
10.49
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.02
2.78
2.78
Orgenesis Inc. stock logo
ORGS
Orgenesis
N/A
0.07
0.07

Institutional Ownership

CompanyInstitutional Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
75.19%
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
7.16%
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
0.66%
Orgenesis Inc. stock logo
ORGS
Orgenesis
22.56%

Insider Ownership

CompanyInsider Ownership
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
8.70%
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
21.72%
Immunome, Inc. stock logo
IMNM
Immunome
8.60%
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2.20%
Orgenesis Inc. stock logo
ORGS
Orgenesis
5.66%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crescent Biopharma, Inc. stock logo
CBIO
Crescent Biopharma
5019.55 million17.85 millionNo Data
Enochian Biosciences Inc. stock logo
ENOB
Enochian Biosciences
2258.28 million45.63 millionNot Optionable
Immunome, Inc. stock logo
IMNM
Immunome
4087.01 million79.53 millionOptionable
Liminal BioSciences Inc. stock logo
LMNL
Liminal BioSciences
2513.10 million3.04 millionNot Optionable
Orgenesis Inc. stock logo
ORGS
Orgenesis
1504.80 million4.53 millionNo Data

Recent News About These Companies

Orgenesis (NASDAQ:ORGS) Trading Down 6.6% - What's Next?
Orgenesis Delays Filing of Quarterly Report
Orgenesis secures $5M equity investment from Williamsburg Venture
Orgenesis Inc. Reports Q3 2024 Financial Results
Orgenesis Provides Third Quarter 2024 Business Update
Orgenesis Expands Board with Three New Appointments
Orgenesis commences trading on OTCQX Best Market
Orgenesis Commences Trading on OTCQX® Best Market
45O.SG,0P0001J8IU,0 (45O.SG)
Why Orgenesis (ORGS) Stock Is Down 23% Today
Orgenesis Inc.: Orgenesis Announces Reverse Stock Split
Orgenesis Approves 1-for-10 Reverse Stock Split
Orgenesis Announces Reverse Stock Split
Is Orgenesis Stock (ORGS) a Good Investment?

New MarketBeat Followers Over Time

Media Sentiment Over Time

Crescent Biopharma stock logo

Crescent Biopharma NASDAQ:CBIO

$15.09 -0.20 (-1.31%)
As of 07/8/2025 04:00 PM Eastern

Crescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.

Enochian Biosciences stock logo

Enochian Biosciences NASDAQ:ENOB

Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Immunome stock logo

Immunome NASDAQ:IMNM

$8.55 -0.14 (-1.61%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$8.64 +0.08 (+0.99%)
As of 07/8/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Liminal BioSciences stock logo

Liminal BioSciences NASDAQ:LMNL

Liminal BioSciences Inc., a development stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company is developing LMNL6511, a selective antagonist for the G-protein coupled receptor 84, is expected to commence a Phase 1 clinical trial. It is also developing potential OXER1 antagonists and GPR40 agonists, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.

Orgenesis stock logo

Orgenesis NASDAQ:ORGS

$1.41 -0.10 (-6.56%)
As of 07/8/2025 11:58 AM Eastern

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.